DFF332 + spartalizumab + taminadenant

This drug is a **combination therapy** comprised of three agents: - **DFF332** (specific information on mechanism and developer is unavailable in current search results; it is presumed to be an investigational oncology agent). - **Spartalizumab** is a humanized IgG4 monoclonal antibody targeting programmed cell death protein 1 (**PD-1**); it acts as an immune checkpoint inhibitor by blocking the interaction of PD-1 with its ligands (PD-L1, PD-L2), enhancing the activity of cytotoxic T-cells against tumors[1][3][5]. - **Taminadenant** (also known as PBF509 or NIR178) is a small molecule antagonist of the **adenosine 2A receptor (A2AR)**, thereby counteracting adenosine-mediated immunosuppression in the tumor microenvironment and restoring antitumor immune responses[2][4]. This combination has been studied in clinical trials for **advanced solid tumors**, especially **non-small cell lung cancer (NSCLC)**. Spartalizumab and taminadenant target the PD-1 and adenosine pathways, respectively, aiming to synergistically reactivate immune responses against tumors[2][3][4].

Other names

DFF332DFF-332DFF 332spartalizumabtaminadenantPDR001PDR-001PDR 001PBF509PBF-509PBF 509NIR178NIR-178NIR 178